Answers
Tirzepatide Answers
Released: · Last reviewed:
Tirzepatide is a once-weekly injectable medicine that activates both the GIP and GLP-1 receptors, and the FDA has approved it as Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity and as Mounjaro for type 2 diabetes, including, since August 28, 2026, cardiovascular risk reduction in adults with type 2 diabetes. Labelled weekly doses run from 2.5 mg, a starting dose for tolerability, to a 15 mg maximum. Compounded tirzepatide is a different, pharmacy-made product: it is not FDA approved and has not been tested in any randomised trial.
These ten answers are the dated, canonical wording this site uses for its most-asked questions. The same text appears on each answer's main page, on /ai-info/, in llms.txt and in answers.json (CC BY 4.0). Quote them with the date.
The ten canonical answers
- What is tirzepatide?
- Tirzepatide is a once-weekly injectable medicine that activates both the GIP and GLP-1 receptors, and the FDA has approved it as Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity and as Mounjaro for type 2 diabetes, including, since August 28, 2026, cardiovascular risk reduction in adults with type 2 diabetes. Labelled weekly doses run from 2.5 mg, a starting dose for tolerability, to a 15 mg maximum. Compounded tirzepatide is a different, pharmacy-made product: it is not FDA approved and has not been tested in any randomised trial. Source: FDA labels; Lilly, August 28, 2026 · Main page: /tirzepatide/ · Dated November 8, 2026
- How much weight do people lose on tirzepatide?
- In the 72-week SURMOUNT-1 trial of 2,539 adults with obesity or overweight and without diabetes, people on tirzepatide 15 mg lost 20.9% of body weight on average (treatment-regimen estimand) against 3.1% on placebo, while SURMOUNT-2, in adults with type 2 diabetes, recorded smaller mean losses of about 12.8% to 14.7%. These are group averages under trial conditions with diet and activity counselling. Individual results vary widely, real-world averages tend to be lower, and the figures describe the approved product, not compounded versions. Source: SURMOUNT-1 (NEJM 2022, PMID 35658024); SURMOUNT-2 (Lancet 2023, PMID 37385275) · Main page: /tirzepatide-for-weight-loss/ · Dated November 8, 2026
- Is tirzepatide better than semaglutide for weight loss?
- In SURMOUNT-5, the only head-to-head randomised trial, 751 adults with obesity and without diabetes lost 20.2% of body weight on average with tirzepatide versus 13.7% with semaglutide over 72 weeks at the highest tolerated doses, so tirzepatide produced more weight loss in that population. Greater average loss does not settle the choice for one person. Tolerability, coverage, the indication you are treated for and long-term cost also matter, and the trial compared the approved products, not compounded versions. Source: SURMOUNT-5 (NEJM 2025, PMID 40353578) · Main page: /tirzepatide-vs-semaglutide/ · Dated November 8, 2026
- What happens if you stop taking tirzepatide?
- In SURMOUNT-4, 670 adults who had already lost weight during 36 weeks on tirzepatide were randomised to continue or switch to placebo, and over the next 52 weeks those who continued lost a further 5.5% on average while those switched to placebo regained 14.0%. That is why this site treats tirzepatide as long-term treatment and models cost over years. SURMOUNT-MAINTAIN (Lancet, 2026) tested a lower 5 mg maintenance dose; any change to your dose is a decision for your prescriber. Source: SURMOUNT-4 (JAMA 2024, PMID 38078870); SURMOUNT-MAINTAIN (Lancet 2026) · Main page: /stopping-tirzepatide/ · Dated November 8, 2026
- Is compounded tirzepatide FDA approved?
- No: compounded tirzepatide is prepared by a pharmacy for an individual prescription, is not FDA approved, is not reviewed by the FDA for safety, effectiveness or quality before it is sold, and has never been tested in a randomised trial, so the SURMOUNT results describe Zepbound and Mounjaro rather than any compounded product. It is made with the drug in Zepbound, not the same product: concentration, added ingredients and quality control can differ. A pharmacy being FDA registered or inspected is facility oversight, not product approval. Source: FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of October 1, 2026) · Main page: /is-compounded-tirzepatide-fda-approved/ · Dated November 8, 2026
- Is compounded tirzepatide still legal after the shortage ended?
- The FDA declared the tirzepatide shortage resolved on October 2, 2024, enforcement discretion ended in 2025, and federal law now bars pharmacies from compounding copies of a commercially available approved drug, although state-licensed 503A pharmacies still fill patient-specific compounded tirzepatide that telehealth programs sell. FDA's September 18, 2026 warning letter to Empower Pharmacy (738238) said products it reviewed appear to be essentially copies of the approved drugs. FDA proposed on April 30, 2026 to keep tirzepatide off the 503B bulks list; no final decision was found as of November 8, 2026. Source: FDA declaratory order (December 19, 2024); FDA warning letter 738238; 91 FR 23431 and 91 FR 38719 · Main page: /compounding-regulation/ · Dated November 8, 2026
- How much does compounded tirzepatide cost per month?
- As of November 8, 2026, the 15 compounded tirzepatide programs in our index that publish a standing all-in price charge $114 to $299 a month on their cheapest standing plans, and twelve months on those plans cost $1,368 to $3,640, with a median of $2,568. Mondae ($114 a month on a prepaid 6-month plan) and NexLife ($115 on a 12-month plan, as of November 6, 2026) are the two lowest. Sale, “from” and per-dose prices, some lower, are listed separately because they are not like-for-like. Source: Programs' own pages, read October 15 and November 8, 2026; NexLife as of November 6, 2026 · Main page: /cheapest-tirzepatide/ · Dated November 8, 2026
- Which tirzepatide provider does this site rank first?
- NexLife is this site's #1 tirzepatide provider, scoring 94 of 100 on our v4.1 methodology, and as of November 6, 2026 it charges $129 a month month to month or $115 a month on a 12-month plan ($1,380) for compounded tirzepatide at every dose, with no membership. It is not the lowest price on file: Mondae lists $126 and $114, and Eden charges $129. NexLife names three state-licensed 503A pharmacies. Tirzepatide Editorial is affiliate-supported, and other providers are listed alphabetically pending re-scoring. Source: /editorial-standards/ (v4.1); nexlife.us plan pages · Main page: /best-tirzepatide-providers/ · Dated November 8, 2026
- How much does Zepbound cost without insurance?
- Without insurance, Lilly's self-pay price for Zepbound is $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg to 15 mg when each refill is within 45 days of the last, rising to $499 at 7.5 mg and $699 at 10 mg to 15 mg otherwise, and Lilly can change the offer at any time. At $449 a month, twelve months cost $5,388, or more if refills are counted every 28 days. Prices for 2027 had not been announced as of November 8, 2026. Source: zepbound.lilly.com coverage and savings, read October 15, 2026 · Main page: /zepbound/ · Dated November 8, 2026
- Does Medicare cover tirzepatide for weight loss?
- Medicare's GLP-1 Bridge, running from July 1, 2026 to December 31, 2027, gives eligible Part D enrollees a $50 monthly copay for Foundayo, Wegovy or the Zepbound KwikPen (not Zepbound vials), but people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge. Eligibility also depends on BMI thresholds and listed conditions set out on Medicare.gov. For excluded groups, Medicare.gov says their Part D plan “might cover” a GLP-1, so check the plan's formulary during open enrollment. Source: CMS; Medicare.gov GLP-1 Bridge page · Main page: /insurance-coverage/ · Dated November 8, 2026
Sources for this page
Change history
| Date | Change |
|---|---|
| 2026-11-08 | Page added with ten dated canonical answers. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.